Bristol Myers Squibb (BMY)

Total Current Liabilities

$18.66B

Quarterly · Period ending: · USD

BMY logo

BMY Total Current Liabilities

Latest reported$18.66B
BMY Quarterly Current Liabilities ($2.13B → $18.66B)
High-resolution chart · PNG

BMY total current liabilities history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Bristol Myers Squibb Total Current Liabilities — Quarterly (USD)
Period endingTotal Current Liabilities (USD)
18,659,000,000
19,158,000,000
23,417,000,000
28,136,000,000
27,528,000,000
24,070,000,000
23,774,000,000
22,638,000,000
23,265,000,000
25,822,000,000
22,262,000,000
23,462,000,000
20,150,000,000
19,085,000,000
21,890,000,000
18,930,000,000
20,915,000,000
22,821,000,000
21,868,000,000
21,460,000,000
18,991,000,000
17,330,000,000
19,080,000,000
20,464,000,000
23,421,000,000
19,232,000,000
18,304,000,000
10,489,000,000
9,711,000,000
8,841,000,000
10,654,000,000
9,694,000,000
9,878,000,000
9,624,000,000
9,563,000,000
9,438,000,000
9,017,000,000
8,494,000,000
8,841,000,000
8,996,000,000
7,885,000,000
7,597,000,000
8,017,000,000
7,158,000,000
7,435,000,000
7,689,000,000
8,461,000,000
8,103,000,000
7,798,000,000
7,521,000,000
12,440,000,000
8,279,000,000
8,354,000,000
8,414,000,000
8,279,000,000
8,195,000,000
6,991,000,000
7,211,000,000
7,780,000,000
7,313,000,000
7,410,000,000
6,755,000,000
6,739,000,000
6,284,000,000
5,908,000,000
6,017,000,000
6,313,000,000
7,392,000,000
6,744,000,000
6,633,000,000
6,710,000,000
6,951,000,000
8,640,000,000
8,443,000,000
8,644,000,000
8,051,000,000
6,689,000,000
6,307,000,000
6,496,000,000
6,165,000,000
5,829,000,000
6,000,000,000
6,890,000,000
6,622,000,000
6,627,000,000
7,849,000,000
9,843,000,000
9,085,000,000
8,443,000,000
7,550,000,000
7,461,000,000
7,612,000,000
8,430,000,000
8,298,000,000
8,487,000,000
8,138,000,000
6,760,000,000
6,807,000,000
11,109,000,000
7,047,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.